Literature DB >> 23011959

Silymarin for HCV infection.

Stephen J Polyak1, Nicholas H Oberlies, Eve-Isabelle Pécheur, Harel Dahari, Peter Ferenci, Jean-Michel Pawlotsky.   

Abstract

Silymarin, an extract of milk thistle seeds, and silymarin-derived compounds have been considered hepatoprotective since the plant was first described in ancient times. Hepatoprotection is defined as several non-mutually exclusive biological activities including antiviral, antioxidant, anti-inflammatory and immunomodulatory functions. Despite clear evidence for silymarin-induced hepatoprotection in cell culture and animal models, evidence for beneficial effects in humans has been equivocal. This review will summarize the current state of knowledge on silymarin in the context of HCV infection. The information was collated from a recent workshop on silibinin in Germany.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011959      PMCID: PMC4076489          DOI: 10.3851/IMP2402

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  44 in total

1.  Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens.

Authors:  R Huber; I Futter; R Lüdtke
Journal:  Eur J Med Res       Date:  2005-02-28       Impact factor: 2.175

2.  Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Authors:  Sarah J Schrieber; Roy L Hawke; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Catherine M Meyers; Edward Doo; Michael W Fried
Journal:  Drug Metab Dispos       Date:  2011-08-24       Impact factor: 3.922

3.  Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy.

Authors:  U P Neumann; M Biermer; D Eurich; P Neuhaus; T Berg
Journal:  J Hepatol       Date:  2010-03-15       Impact factor: 25.083

4.  Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers.

Authors:  G Gatti; E Perucca
Journal:  Int J Clin Pharmacol Ther       Date:  1994-11       Impact factor: 1.366

5.  A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis.

Authors:  G Buzzelli; S Moscarella; A Giusti; A Duchini; C Marena; M Lampertico
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1993-09

6.  Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Authors:  Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

7.  Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.

Authors:  Zhiming Wen; Todd E Dumas; Sarah J Schrieber; Roy L Hawke; Michael W Fried; Philip C Smith
Journal:  Drug Metab Dispos       Date:  2007-10-03       Impact factor: 3.922

8.  Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.

Authors:  Adam Gordon; Daryl A Hobbs; D Scott Bowden; Michael J Bailey; Joanne Mitchell; Andrew J P Francis; Stuart K Roberts
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

9.  Multiple effects of silymarin on the hepatitis C virus lifecycle.

Authors:  Jessica Wagoner; Amina Negash; Olivia J Kane; Laura E Martinez; Yaakov Nahmias; Nigel Bourne; David M Owen; Joe Grove; Claire Brimacombe; Jane A McKeating; Eve-Isabelle Pécheur; Tyler N Graf; Nicholas H Oberlies; Volker Lohmann; Feng Cao; John E Tavis; Stephen J Polyak
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

10.  Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Abdelhakim Ahmed-Belkacem; Nazim Ahnou; Laetitia Barbotte; Czeslaw Wychowski; Coralie Pallier; Rozenn Brillet; Ralf-Torsten Pohl; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2009-12-04       Impact factor: 22.682

View more
  22 in total

1.  Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.

Authors:  Brandon T Gufford; Tyler N Graf; Noemi D Paguigan; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-08-27       Impact factor: 3.922

2.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

3.  Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism.

Authors:  Janela McClure; Daciana H Margineantu; Ian R Sweet; Stephen J Polyak
Journal:  Virology       Date:  2013-11-27       Impact factor: 3.616

4.  Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.

Authors:  Marie-Emmanuelle Sahuc; Ramla Sahli; Céline Rivière; Véronique Pène; Muriel Lavie; Alexandre Vandeputte; Priscille Brodin; Arielle R Rosenberg; Jean Dubuisson; Riadh Ksouri; Yves Rouillé; Sevser Sahpaz; Karin Séron
Journal:  J Virol       Date:  2019-05-01       Impact factor: 5.103

Review 5.  Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites.

Authors:  Tariq Khan; Mubarak Ali Khan; Zia-Ur-Rehman Mashwani; Nazif Ullah; Akhtar Nadhman
Journal:  Biocatal Agric Biotechnol       Date:  2020-12-11

6.  Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction.

Authors:  Brandon T Gufford; Gang Chen; Ana G Vergara; Philip Lazarus; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-06-12       Impact factor: 3.922

7.  A validated UHPLC-tandem mass spectrometry method for quantitative analysis of flavonolignans in milk thistle (Silybum marianum) extracts.

Authors:  Tyler N Graf; Nadja B Cech; Stephen J Polyak; Nicholas H Oberlies
Journal:  J Pharm Biomed Anal       Date:  2016-04-22       Impact factor: 3.935

8.  Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.

Authors:  Hanan S Althagafy; Tyler N Graf; Arlene A Sy-Cordero; Brandon T Gufford; Mary F Paine; Jessica Wagoner; Stephen J Polyak; Mitchell P Croatt; Nicholas H Oberlies
Journal:  Bioorg Med Chem       Date:  2013-04-16       Impact factor: 3.641

9.  Mechanistic study of the biomimetic synthesis of flavonolignan diastereoisomers in milk thistle.

Authors:  Hanan S Althagafy; Maria Elena Meza-Aviña; Nicholas H Oberlies; Mitchell P Croatt
Journal:  J Org Chem       Date:  2013-07-22       Impact factor: 4.354

10.  HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case.

Authors:  José G Napolitano; David C Lankin; Tyler N Graf; J Brent Friesen; Shao-Nong Chen; James B McAlpine; Nicholas H Oberlies; Guido F Pauli
Journal:  J Org Chem       Date:  2013-03-05       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.